Bronchial Artery Embolization For Massive Hemoptysis Research Articles

Embolization with more diluted glue-lipiodol in patients with massive hemoptysis: single center experience results.

The aim of the study was to demonstrate the efficacy and safety of bronchial artery embolization (BAE) with more diluted N-butyl-2- cyanoacrylate (NBCA) in patients with massive hemoptysis. In this retrospective study, there are 48 patients who underwent NBCA and BAE for massive hemoptysis between March 2018 and September 2021. Demographic data, technical and clinical results, immediate hemoptysis control, recurrent hemoptysis and complications were evaluated. The technical success rate and immediate hemoptysis control were achieved in 97.9% and 93.7%, respectively. The 3 patients who were exitus within the first 10 days were removed from the follow-up range. During the follow-up period (range, 5 months-42 months; median, 27.5 months), recurrent hemoptysis was found in 3 of the 45 patients (6.6 %). Since 1 patient refused and one patient died within the first 24 hours, repeated BAE procedures were performed in 4 patients. A total of 55 sessions of BAE with NBCA was performed to 48 patients. The underlying diseases causing hemoptysis were determined to be bronchiectasis (n=16), tuberculosis (n=8), neoplasm (n=7), aspergilloma (n=3), and arteriovenous malformation (n=2). In 4 patients, bronchiectasis and tuberculosis were present together and in 8 patients, the cause could not be specified. In conclusion, BAE with more diluted NBCA is a safe and effective embolization method. In addition, the use of more diluted NBCA reduces the recurrence rates in patients with hemoptysis.

The long-term effect of embolization of bronchial artery in patients with massive hemoptysis

Objective To explore the long-term effect of bronchial artery, embolization (BAE) in patients with massive hemoptysis and the factors associated with prognosis. Methods Ninety six patients underwent BAE from 2002 to 2008 for the management of mass hemoptysis were retrospectively analyzed. Of them, BAE was successfully performed in 94 patients (mean age 43 years, age range 21 to 80 years), including active or inactive tuberculosis (89 cases), bronchiectasis (2 cases) and pulmonary carcinoma (5 cases). Results BAE resulted in an immediate cessation of hemoptysis in 94 of the initial 96 patients (97.9%). The rate of hemoptysis controlling at 30 d, 90 d, 1 year and 2 year after the BAE was 93.6% (88/94), 86. 2% (81/94), 81.9% (77/94) and 78.7% (74/94) respectively. Haemoptysis recurred in 9 patients in 30 days after the BAE due to missing of target vessel or recanalization. Five patients had recurrence of haemoptysis after 30 days and 2 patients recurrent after 90 days due to development of systemic collateral, progress in primary lesions and secondary infection. Conclusion BAE is an effective technique in the emergency treatment of massive hemoptysis. Avoiding missing target vessel, selecting the appropriate embolic material, paying attention to treatment of the primary disease after BAE, and preventing infection would improve the effects of BAE for massive hemoptysis. Key words: Hemoptysis; Bronchial arteries; Embolization, therapeutic